RS63514B1 - Jedinjenja korisna kao ret inhibitori - Google Patents

Jedinjenja korisna kao ret inhibitori

Info

Publication number
RS63514B1
RS63514B1 RS20220789A RSP20220789A RS63514B1 RS 63514 B1 RS63514 B1 RS 63514B1 RS 20220789 A RS20220789 A RS 20220789A RS P20220789 A RSP20220789 A RS P20220789A RS 63514 B1 RS63514 B1 RS 63514B1
Authority
RS
Serbia
Prior art keywords
compounds useful
ret inhibitors
ret
inhibitors
compounds
Prior art date
Application number
RS20220789A
Other languages
English (en)
Inventor
Allan Jordan
Rebecca Newton
George Hynd
Jonathan Mark Sutton
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of RS63514B1 publication Critical patent/RS63514B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20220789A 2017-04-13 2018-04-13 Jedinjenja korisna kao ret inhibitori RS63514B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705971.8A GB201705971D0 (en) 2017-04-13 2017-04-13 Inhibitor compounds
EP18719276.0A EP3609898B1 (en) 2017-04-13 2018-04-13 Compounds useful as ret inhibitors
PCT/GB2018/050986 WO2018189553A1 (en) 2017-04-13 2018-04-13 Compounds useful as ret inhibitors

Publications (1)

Publication Number Publication Date
RS63514B1 true RS63514B1 (sr) 2022-09-30

Family

ID=58744532

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220789A RS63514B1 (sr) 2017-04-13 2018-04-13 Jedinjenja korisna kao ret inhibitori

Country Status (19)

Country Link
US (3) US11352361B2 (sr)
EP (2) EP4105219A1 (sr)
JP (2) JP7277376B2 (sr)
CN (2) CN115785100A (sr)
AU (3) AU2018252251B2 (sr)
BR (1) BR112019021231A2 (sr)
CA (1) CA3059134A1 (sr)
DK (1) DK3609898T3 (sr)
ES (1) ES2925077T3 (sr)
GB (1) GB201705971D0 (sr)
HR (1) HRP20221040T1 (sr)
HU (1) HUE059716T2 (sr)
LT (1) LT3609898T (sr)
PL (1) PL3609898T3 (sr)
PT (1) PT3609898T (sr)
RS (1) RS63514B1 (sr)
RU (1) RU2760669C2 (sr)
SI (1) SI3609898T1 (sr)
WO (1) WO2018189553A1 (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194262A (en) 2015-11-02 2022-11-25 Blueprint Medicines Corp Inhibitors of ret
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
BR112021019643A2 (pt) * 2019-04-03 2021-12-07 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
EP4194455A4 (en) * 2020-09-29 2024-04-03 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory CRYSTALLINE FORMS OF PYRIDOPYRAZOLE COMPOUNDS AND PRODUCTION PROCESSES THEREOF
WO2023287704A1 (en) * 2021-07-12 2023-01-19 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
WO2023064843A1 (en) * 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153325A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
MY148491A (en) 2005-11-17 2013-04-30 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
EP2528919B1 (en) 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20110304649A1 (en) 2010-06-10 2011-12-15 Microsoft Corporation Character selection
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US20140357651A1 (en) 2011-05-04 2014-12-04 Yi Liu Combination pharmaceutical compositions and uses thereof
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
EP2776441A4 (en) 2011-11-08 2015-04-08 Intellikine Llc TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
EP2997030B1 (en) * 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
PL3218378T3 (pl) * 2014-11-14 2020-10-19 Nerviano Medical Sciences S.R.L. Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
CA2974702C (en) 2015-01-26 2023-10-10 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
PL3442535T3 (pl) 2016-04-15 2022-10-24 Cancer Research Technology Limited Związki heterocykliczne jako inhibitory kinazy ret
MX2018012609A (es) 2016-04-15 2019-08-01 Cancer Research Tech Ltd Compuestos heterociclicos como inhibidores de la cinasa ret.
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
RU2019132155A (ru) 2021-05-13
BR112019021231A2 (pt) 2020-04-28
PT3609898T (pt) 2022-08-25
JP7536949B2 (ja) 2024-08-20
ES2925077T3 (es) 2022-10-13
JP2023103326A (ja) 2023-07-26
EP3609898B1 (en) 2022-06-01
AU2018252251A1 (en) 2019-10-17
CA3059134A1 (en) 2018-10-18
JP7277376B2 (ja) 2023-05-18
AU2022202325A1 (en) 2022-04-28
HRP20221040T1 (hr) 2022-11-11
AU2022202325B2 (en) 2024-05-23
RU2019132155A3 (sr) 2021-05-13
GB201705971D0 (en) 2017-05-31
US11352361B2 (en) 2022-06-07
LT3609898T (lt) 2022-09-12
US20220348585A1 (en) 2022-11-03
AU2024213175A1 (en) 2024-09-12
SI3609898T1 (sl) 2022-11-30
US20200157107A1 (en) 2020-05-21
EP4105219A1 (en) 2022-12-21
CN115785100A (zh) 2023-03-14
DK3609898T3 (da) 2022-09-05
AU2018252251B2 (en) 2022-03-31
WO2018189553A1 (en) 2018-10-18
PL3609898T3 (pl) 2022-09-26
US11680068B2 (en) 2023-06-20
CN110506043A (zh) 2019-11-26
EP3609898A1 (en) 2020-02-19
JP2020516636A (ja) 2020-06-11
RU2760669C2 (ru) 2021-11-29
US20240132504A1 (en) 2024-04-25
HUE059716T2 (hu) 2022-12-28
CN110506043B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
PT3609898T (pt) Compostos úteis como inibidores de ret
PL3371190T3 (pl) Związki heterocykliczne jako inhibitory pi3k-gamma
ZA201708244B (en) Thioether compounds as nitrification inhibitors
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
IL274821A (en) Substances that inhibit MPGES-1 and their uses
PT3589637T (pt) Compostos úteis para inibir ror-gamma-t
LT3589638T (lt) Junginiai, naudingi ror-gama-t slopinimui
GB201720145D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201522245D0 (en) Compounds useful as kinase inhibitors